poster
Beta-cyclodextrin is a commonly used excipient in nonclinical vehicle formulations. In a recent study, vehicle formulated with 35% HP-β-CD resulted in hemolysis after a 5–10-minute
intravenous (IV) infusion in Sprague Dawley rats, as evidenced by red urine, increased serum bilirubin levels, and increased clinical pathology hemolysis scores.
During subcutaneous (SC) administration using 11.6% HP-β-CD, hemolysis did not occur, though histopathological changes at the injection site indicated local toxicity (edema, mixed inflammation, hemorrhage, and myofiber degeneration) 24 hours post dose.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.